- Home
- FATE vs MCRB Comparison
FATE vs MCRB Comparison
Compare FATE & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FATE | MCRB |
|---|---|---|
| Founded | 2007 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.6M | 139.7M |
| IPO Year | 2013 | 2015 |
Fundamental Metrics
Financial Performance| Metric | FATE | MCRB |
|---|---|---|
| Price | $1.21 | $15.10 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 3 |
| Target Price | $3.92 | ★ $14.33 |
| AVG Volume (30 Days) | ★ 1.8M | 44.1K |
| Earning Date | 03-04-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.62 |
| Revenue | ★ $7,137,000.00 | $351,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $24.45 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.66 | $6.53 |
| 52 Week High | $1.94 | $29.98 |
Technical Indicators
Market Signals| Indicator | FATE | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 53.84 | 46.01 |
| Support Level | $1.17 | $14.50 |
| Resistance Level | $1.32 | $15.90 |
| Average True Range (ATR) | 0.08 | 0.87 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 53.33 | 33.33 |
Price Performance
Historical ComparisonAbout FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.